Portfolio company
Alia Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops gene editing medicines for patients with genetic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Borea Therapeutics
The company develops bio-conjugated viral vectors for gene therapy to treat patients with genetic or chronic diseases.
Immitra Bio
This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
LogicBio
This company develops gene editing and delivery platforms to provide one-time treatments for patients with serious, early-onset rare genetic diseases.
Beam Therapeutics
The company develops precision genetic medicines using base editing technology to treat patients with serious genetic diseases such as sickle cell disease.
Metagenomi
Metagenomi develops genome editing tools and genetic medicines for patients with genetic mutations.